The Effect of Efavirenz on Estradiol Metabolism in Transgender Women | Zendy

Matthew C. Leinung | Zendy; Cynthia H. Miller | Zendy; Babak Tehrani | Zendy; Jalaja Joseph | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effect of Efavirenz on Estradiol Metabolism in Transgender Women

Author(s) -

Matthew C. Leinung,

Cynthia H. Miller,

Babak Tehrani,

Jalaja Joseph

Publication year - 2019

Publication title -

transgender health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.242

H-Index - 20

eISSN - 2688-4887

pISSN - 2380-193X

DOI - 10.1089/trgh.2019.0018

Subject(s) - transgender , efavirenz , transgender women , physiology , endocrinology , medicine , gender studies , sociology , human immunodeficiency virus (hiv) , virology , syphilis , men who have sex with men , viral load , antiretroviral therapy

The goal of hormonal therapy in treating gender dysphoria is to maintain cross-sex hormone levels in the normal physiological range for the desired gender. Estrogen is the mainstay of hormonal therapy for male to female transgender patients. Efavirenz, a non-nucleoside reverse-transcriptase inhibitor, has been one of the most commonly prescribed antiretroviral therapies (ARTs). However, this regimen has also given rise to the most clinically significant drug-drug interactions between ARTs and hormone-based contraceptives. We discuss here three transgender HIV-positive women in whom efavirenz effected the metabolism of orally administered estradiol (and probably medroxyprogesterone).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research